Emma Mueller, Author at The Boomer Esiason Foundation

March 19, 2019

The CF Foundation has learned that the U.S. Food and Drug Administration will allow wholesalers to distribute the pancreatic enzyme product Pancrease® MT to pharmacies until July 12, 2010. At that time, an updated formula called PancreazeTM will become available and will replace Pancrease. Several days...

Pancreatic Enzyme Therapy Pancrease to Have Limited Availability, CFF Says

by Emma Mueller

CF News, Therapies

March 19, 2019

The Cystic Fibrosis Foundation has learned that the pancreatic enzyme product Pancrease will be available in limited supply at pharmacies around the country until an updated formula called Pancreaze™ is made available this summer. Pancreaze is manufactured by Johnson and Johnson Pharmaceutical Research and Development. The CF...

Data Suggest Denufosol May Hold Promise as an Early Intervention Treatment for CF

by Emma Mueller

CF News, Therapies

March 19, 2019

Inspire Pharmaceuticals, Inc. announced today that Inspire scientists and collaborators will present data on denufosol tetrasodium, an investigational therapy for cystic fibrosis (CF), during an oral presentation at the American Thoracic Society (ATS) 2010 International Conference May 14 - 19, 2010 in New Orleans, LA....

Mpex Presents Positive Phase 2 Clinical Trial Results of Aeroquin Treatment in CF

by Emma Mueller

CF News, Therapies

March 19, 2019

Mpex Pharmaceuticals, Inc. today announced the presentation of data from its Phase 2b clinical trial with Aeroquin™ (a proprietary aerosol formulation of levofloxacin, MP-376) in cystic fibrosis (CF) at the American Thoracic Society (ATS) Annual Meeting in New Orleans. Trial results demonstrated statistically significant improvements...

Azithromycin Doesn’t Always Help Lungs in CF Patients Without P. Aeruginosa, Study Finds

by Emma Mueller

CF News, Therapies

March 19, 2019

Children and adolescents with cystic fibrosis who received the antibiotic azithromycin did not experience improved lung function, compared with patients who received placebo, according to a study published in the May 5 issue of the Journal of the American Medical Association. "A vicious cycle of infection...

Raptor Announces Qualified Infectious Disease Product

by Emma Mueller

CF Community, CF News, Research, Therapies

March 19, 2019

SOURCE: Original Press Release Raptor Announces Qualified Infectious Disease Product (QIDP) Designation for MP-376, Inhaled LevofloxacinGranted for Three Distinct Indications: Chronic Pulmonary Infections Due to Pseudomonas Aeruginosa in Patients with Cystic Fibrosis and in Patients with Non-Cystic Fibrosis Bronchiectasis as well as in Patients with Nontuberculous MycobacteriaPre-NDA Discussion...

Kalydeco Wins First Annual Forbes Breakthrough Drug Award via Forbes.com

by Emma Mueller

Boomer Esiason Foundation, CF Community, CF News, Research, Therapies

March 19, 2019

SOURCEKalydeco, a treatment for cystic fibrosis developed by Vertex Pharmaceuticals VRTX +2.40% with support from the Cystic Fibrosis Foundation , was awarded the first Forbes Breakthrough Drug Award today for dramatically improving the lives of patients and conquering a scientific challenge that had vexed researchers...

CF Mutation May Change How Proteins Communicate via CF News Today

by Emma Mueller

CF Community, CF News, Research

March 19, 2019

Original Post Protein interactions could be misdirected in people with cystic fibrosis (CF), causing a loss of normal protein function, according to researchers from the Scripps Research Institute (TSRI) in San Diego, California. The new study, titled “∆F508 CFTR interactome remodelling promotes rescue of cystic fibrosis“...

Vertex Announces Significant Progress in Development via Vertex

by Emma Mueller

CF Community, CF News, Research, Therapies

March 19, 2019

SOURCE - OFFICIAL PRESS RELEASE Vertex Announces Significant Progress in Its Development Efforts to Treat the Cause of Cystic Fibrosis in the Vast Majority of People with the Disease-Two next-generation correctors to enter clinical development in November; studies of a triple combination of a next-generation corrector...

ORKAMBI™ Is Now FDA Approved!

by Emma Mueller

CF Community, CF News, Research, Therapies

March 19, 2019

ORKAMBI is a prescription medicine used for the treatment of cystic fibrosis (CF) in patients age 12 years and older who have two copies of the F508del mutation (F508del/F508del) in their CFTR gene. ORKAMBI should not be used in patients other than those who have two...

Author: Emma Mueller

FDA Extends Availability of Pancreatic Enzyme Therapy Pancrease Until Mid-July

Pancreatic Enzyme Therapy Pancrease to Have Limited Availability, CFF Says

Data Suggest Denufosol May Hold Promise as an Early Intervention Treatment for CF

Mpex Presents Positive Phase 2 Clinical Trial Results of Aeroquin Treatment in CF

Azithromycin Doesn’t Always Help Lungs in CF Patients Without P. Aeruginosa, Study Finds

Raptor Announces Qualified Infectious Disease Product

Kalydeco Wins First Annual Forbes Breakthrough Drug Award via Forbes.com

CF Mutation May Change How Proteins Communicate via CF News Today

Vertex Announces Significant Progress in Development via Vertex

ORKAMBI™ Is Now FDA Approved!

Never miss an update. Subscribe to our emails!